Gene Inhibition Therapy

Therapeutic Triggers of RNAi

Therapeutic triggers of RNAi can be used as therapeutic strategies.

In this video, we will review the therapeutic triggers of RNAi and how these have been harnessed as therapeutic strategies.

Therapeutic triggers of RNAi include synthetic siRNAs or transgenes expressing hairpin-based inhibitory RNAs such as short hairpin RNAs (or shRNAs) and artificial microRNAs1,2.

Let’s briefly talk about synthetic siRNAs. Synthetic siRNAs are synthesized as double-stranded RNAs, 21 to 23 base pairs long, that have two 3-prime overhangs that are 2 nucleotides long1,3,4.

For therapeutic purposes, synthetic siRNAs can be artificially introduced into cells, where they are processed by the endogenous RNAi pathway as portrayed in Section 2. siRNAs associate with RISC and are processed further within the siRNA–RISC complex, leading to cleavage of the target mRNA1,3.

A limitation to the use of synthetic siRNAs is their transient nature, with intracellular siRNA concentrations declining very rapidly, thus requiring repetitive dosing2,5. Synthetic siRNAs have been investigated in several diseases including polyneuropathy and amyotrophic lateral sclerosis, among many others6,7. As an example, in August 2018, a transthyretin-directed siRNA was approved in the United States for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis, a genetic disorder caused by dysfunctional transthyretin protein in the liver8,9. However, as synthetic siRNAs do not fall within the scope of gene therapy, they will not be discussed further in this video10-12.

shRNAs are hairpin structures that contain two complementary RNA sequences 19 to 22 base pairs long. These are linked by a short loop of 4 to 11 nucleotides and have one 3-prime overhang that is 2 nucleotides long13,14. The first generation of shRNAs are similar in structure to the naturally occurring pre-microRNA14,15.

shRNA complementary DNA (or cDNA) can be delivered into the cell via a viral vector or plasmid, which allows for prolonged gene inhibition13,16,17. shRNAs are usually transcribed by polymerase III, or sometimes polymerase II, to form the hairpin structures; the transcribed product is then directly transported into the cytoplasm where the loop is cleaved to form siRNA2,14,18. siRNAs then associate with RISC for mRNA cleavage activity in the same way as described in the endogenous pathway18. As shRNAs are generally designed to have perfect complementarity to mRNA sites, shRNAs cause gene inhibition via direct cleavage of the target mRNA at the site of complementarity14,18.

Now let’s talk about artificial microRNAs, a third type of therapeutic double-stranded RNA that can be used to trigger RNAi19. Artificial microRNAs are cellular microRNAs that have been modified to create partial complementarity to a target mRNA2. They are hairpin structures containing two complementary 19 to 25 base pair RNA sequences with interspaced mismatches, and a 5-prime and a 3-prime overhang2,3,20.

Artificial microRNAs can be introduced into the cells via an expression cassette containing the artificial microRNA cDNA or in a delivery vector such as an adeno-associated virus2. They can be transcribed by RNA polymerase II or III promoters, which are also included in the expression cassette21,22. Therapeutic strategies using artificial microRNAs aim to achieve the same biological functions as the endogenous microRNAs, and follow the natural microRNA signaling pathway3. Artificial microRNAs associate with RISC and are processed further to lead to inhibition of the target mRNA3. Because they have partial complementarity to the target mRNA, artificial microRNAs can induce gene inhibition via translational repression, mRNA degradation, or mRNA cleavage2,3,23. This summarizes key therapeutic triggers of RNAi. The next section will discuss key differences between shRNA and artificial microRNA.


  1. Sibley C, et al. Mol Ther 2010;18(3):466–476.
  2. Borel F, et al. Mol Ther 2014;22(4):692–701.
  3. Lam JK, et al. Mol Ther Nucleic Acids 2015;4:e252.
  4. Laganà A, et al. Front Bioeng Biotechnol 2014;2:65.
  5. Grimm D, Kay MA. Hematology Am Soc Educ Program 2007;2007:473–481.
  6. Pushparaj PN, et al. J Dent Res 2008;87(11):992–1003.
  7. Chakraborty C, et al. Mol Ther Nucleic Acids 2017;8:132–143.
  8. Alnylam Pharmaceuticals. Press release. August 10, 2018. Available at: Accessed March 31, 2020.
  9. Onpattro® [package insert]. 2018. Available at: Accessed March 31, 2020.
  10. Sliva K, Schnierle BS. Virol J 2010;7:248.
  11. Wang J, et al. AAPS J 2010;12(4):492–503.
  12. U.S. FDA. Approved Cellular and Gene Therapy Products. Available at:
  13. Moore CB, et al. Methods Mol Biol 2010;629:141–158.
  14. Bofill-De Ros X, Gu S. Methods 2016;103:157–166.
  15. Myburgh R, et al. Mol Ther Nucl Acids 2014;3:e207.
  16. Chen X, et al. Cancer Metastasis Rev 2018;37(1):107–124.
  17. Kurreck J. J RNAi Gene Silencing 2017;13:545–547.
  18. Rao DD, et al. Adv Drug Del Rev 2009;61:746–759.
  19. Wang D, Gao G. Discov Med 2014;18(98):151–161.
  20. Boudreau RL, et al. Mol Ther 2009;17(1):169–175.
  21. Park JH, Shin C. BMB Rep 2014;47(8):417–423.
  22. Fan J, et al. Cancer Gene Ther 2019. doi: 10.1038/s41417-019-0113-y [Epub ahead of print].
  23. Merlin S, Follenzi AT. Mol Ther Meth Clin Dev 2019;12:223–232.